Seventy artifacts from a fictional seven-gate FDA drug development program — VitaFlow (VTX-401), a once-weekly GLP-1 receptor agonist for chronic weight management, carried from discovery through Phase 3 conduct, NDA submission, launch and closure against a $243,040,000 authorized ceiling. Every figure on every page derives from a single locked fact base that refuses to build if the numbers stop reconciling. Each artifact is a live page plus a downloadable Word, Excel, or PowerPoint file.
- A. Program Governance
- B. Business Case & Finance
- C. Schedule, Scope & Resource
- D. Regulatory
- E. Clinical Development
- F. Clinical Data, Statistics & Supply
- G. CMC & Quality
- H. Risk & Control
- I. Status & Reporting
- J. Commercial & Launch
- K. Delivery & Closure — forward-dated end-state
- L. Reference
- Background
Program Governance
Program Charter
The authorizing instrument. Scope, governance, funding ceiling, and the limits of authority.
Development Committee Charter
Mandate, quorum, voting rules, conflict handling, and the five defined gate outcomes.
Gate Decision Framework
Must-meet and should-meet criteria per gate, scoring method, and the recorded decision standard.
RACI Matrix
16 decisions against 8 roles, exactly one accountable party per row — only two of them the Program Director's, and four placed outside the program.
Business Case & Finance
Gate 4 Business Case Package
Why expected value at Gate 0 was below the cost of finding out, the assumption stack, sensitivity in which cost is the least important driver, and what is not claimed.
Program Budget
Cost pools, stage tranches, contingency register, and spend against release.
Schedule, Scope & Resource
Project Management Plan
The consolidated plan — how scope, schedule, cost, quality, resource, communication, risk and procurement will be managed, the three baselines and who may move them, and the five places subsidiary plans conflict.
Scope Baseline & WBS Dictionary
The approved scope frozen at Gate 4: what is in, what is explicitly out and why, the WBS dictionary with each account's exclusions, and acceptance criteria.
Organization Chart & OBS
Organizational breakdown structure, reporting lines, the three independence lines, and how the OBS intersects the WBS to form control accounts.
Work Breakdown Structure
Deliverable hierarchy by stage, resource-loaded, tying to the roster envelopes.
Integrated Development Schedule
Clinical, CMC and regulatory tracks with a derived Gantt, the critical path and where it changes hands, and the Phase 2 feasibility contract enforced at build time.
Resource Plan
The roster by function and by stage: headcount against concurrent FTE, hours reconciled both directions, and the internal/external split.
Basis of Estimate
Method, cost driver, source and accuracy class for every pool — and why contingency is an output of the estimate mix rather than a round number.
Procurement & Sourcing Plan
Make-versus-buy, how vendors were selected, which contract model carries which risk, the agreements register, and what cannot be bought.
Regulatory
Regulatory Strategy
The 505(b)(1) pathway rationale, review assumptions, and the filing footprint.
FDA Interaction Log
Every meeting, the questions taken, the agency position recorded, and what changed as a result.
IND Summary
The IND-enabling package as filed, and what the thirty-day review returned.
NDA Readiness Assessment
What gates each of the five eCTD modules, the eleven-week sequence that cannot be compressed, and the five grounds for refuse-to-file.
Clinical Development
Phase 3 Protocol Summary
Design, endpoints, population, and the statistical analysis plan in outline.
Data Monitoring Committee Charter
Composition, review cadence, stopping rules, and the authority boundary against governance.
Enrolment & Site Dashboard
Randomization against curve, site activation, and screen-failure trending.
Site Selection & Management Plan
Selection criteria, activation sequence, monitoring model, and the reserve list.
Safety Reporting Plan
Expedited reporting obligations, causality assessment, and the signal detection process.
Clinical Data, Statistics & Supply
Trial Master File Plan
The essential-document record across the 11 zones of the DIA TMF Reference Model — filing windows, how completeness is known, and inspection readiness.
Data Management Plan
EDC design, edit checks, medical coding dictionaries, external data reconciliation, SAE reconciliation, and the database lock sequence.
Statistical Analysis Plan Summary
Analysis sets, the testing hierarchy, estimands, handling of missing data, and why the SAP must be signed before unblinding. Per ICH E9.
Randomization & Clinical Supply Plan
Randomization scheme and RTSM, blinding integrity, investigational product labeling, distribution, accountability, return and destruction.
Clinical Study Report Summary
ICH E3 structure, which reports exist at the status date and which cannot yet, how every number traces to source, and what makes a CSR fail review.
IRB / Ethics & Informed Consent Plan
Central versus local review and what it costs the schedule, which sponsor levers actually work, consent versioning, and the approvals record.
CMC & Quality
CMC Readiness Assessment
Drug substance, drug product, analytical methods, and the registration-batch position.
Process Validation Plan
Validation strategy and the sequence that gates the pre-approval inspection (DEP-04).
Stability Program
ICH stability design and the shelf-life claim the dossier will support.
GxP Compliance Plan
GLP, GCP and cGMP obligations mapped to owners and audit cadence.
Risk & Control
RAID Log
Risks, assumptions, issues, decisions and dependencies with owners and movement between gates.
Gate Conditions Register
Every condition issued at a gate, its evidence standard, owner, and closure record.
Change Request Records
The full form behind every register line — description, driver, options including do-nothing, impact across six dimensions, decision and verification.
Change Control Register
Two approved and four declined with reasoning — including the head-to-head decline that became the program's largest what-if.
Requirements Traceability Matrix
Every TPP attribute traced to the endpoint, analysis, report section and label claim — including the chains that are complete and still carry no weight.
Status & Reporting
Performance Measurement Baseline & EVM
Earned value for the internal labor envelope only — CPI, TCPI, forecast at completion, and why the schedule half of earned value does not work here.
Phase 3 Mobilization Kickoff
The Stage 4 kickoff given at Gate 4 — 20 slides, four timescales from the molecule's 21-year arc down to the 27 months this team executes.
Steering Committee Deck
The Stage 4 checkpoint deck — generated from the fact base, with the ask on slide 2 and a real PowerPoint download.
Risk Report
The register read as an analysis: quantified exposure, eight quarters of trend, which risks are managed rather than merely recorded, and what a register cannot hold.
Program Dashboard
Nine leading indicators with twelve months of trend, what each predicts and how far ahead, and the measures deliberately excluded.
Program Status Report
The periodic report to the Committee: a RAG rule fixed at Gate 4, automatic escalation after three amber periods, and the decisions being asked for.
Commercial & Launch
Market Access & Evidence Plan
Who actually decides coverage, which required evidence cannot be delivered, the formulary cycle that closes before approval, and what GC-03 could not fix.
Launch Readiness Assessment
What was committed before approval existed, which exposures are destroyable and which are merely timing, and what readiness cannot buy.
Delivery & Closure — forward-dated end-state
Gate 5 Decision Record
The NDA submission gate: pivotal results tabled, criteria assessed, outcome and vote.
NDA Submission Summary
What was filed, module by module, and the 60-day filing acceptance.
FDA Review Log
The review cycle: information requests, responses, labeling negotiation, action date.
Gate 6 Decision Record
Approval and launch authorization: inspection closure, supply release, field readiness.
Launch Execution Report
First shipment through the opening commercial period: supply, channel, uptake, field deployment.
Post-Launch Review
Actuals against the Gate 4 forecast, final accounting, and lessons recorded at closure.
Benefits Realization Review
Whether the program delivered what its business case claimed, measured post-launch.
Reference
Product Definition
Target product profile, mechanism, formulation, and the indication as it will be sought.
Drug Development Lifecycle Guide
Plain-English orientation to the FDA pathway — nonclinical through launch, who does what, and where program management fits. Start here if pharma is new to you.
Stage-Gate Methodology Guide
Stage-gate in plain English — why gates belong where uncertainty resolves, six ways the system fails, and where the model is the wrong choice.
Program Story
The narrative arc from candidate selection to filing, including what went wrong.
Glossary
45 terms across five domains — with 31 of them flagging the distinction that is commonly got wrong.
How this program is structured
⚠ The eight delivery artifacts are explicitly forward-dated and are deliberately not reconciled against the in-flight set. That disagreement is intentional and is explained in the program story.
Vitalis Therapeutics Inc. — a fictional pharmaceutical development program, built as a program management portfolio artifact. VitaFlow (VTX-401) is a GLP-1 receptor agonist for chronic weight management, run as a seven-gate FDA development program with a $243,040,000 authorized ceiling and a 109-person roster. The suite below is the governance record as it would stand at 15 October 2026, with the program inside Stage 4 and the NDA gate pending.
What this is
Seventy documents that a real drug development program would produce, written as that program would have written them, for a molecule that does not exist.
The methodology is real: the gate structure, the criteria model, the condition mechanics, the tranche discipline, the regulatory obligations. The pharmacology is a setting — chosen because it makes the methodology concrete, and calibrated against published data so that a reader who works in the field is not distracted by implausibility. Every quantitative parameter traces to a source recorded in Sources & Benchmarks.
It is generated, not written. Every figure derives from a single locked fact base that asserts its own arithmetic on load — cost pools reconcile to base, tranches reconcile to base, the cost-by-stage matrix reconciles in both directions, and the business case is computed by a cash-flow model that aborts if it cannot reproduce the locked figures. If any identity breaks, every artifact in the suite fails to build rather than publishing a number that does not tie.
It records what went wrong. The program has an open gate condition, a second one at risk, enrolment behind curve, and a scope addition that cost $7.2M from contingency. None of that is hidden, because a governance record that surfaces only good news is not a governance record.
Why a drug program is gated
Of drugs entering Phase 1, roughly 7% reach approval. Every structural feature of this program follows from that number — and it can be stated as an inequality.
| At Gate 0 | Value |
|---|---|
| Expected value of the program | $96.0M |
| Authorized cost of finding out | $243,040,000 |
| The expected value was less than the cost. |
So funding is released one stage at a time, and each gate that resolves a conditional raises the expected value: $96.0M at Gate 0, $204.3M at Gate 3, $681.0M at Gate 4 — against $141.6M of authorization still to release. The funding follows the information rather than preceding it.
The derivation is in the Program Charter §2 and computed in the model that underpins it.
Why the gates sit where they do
Most stage-gate models are drawn against a generic project lifecycle: concept, plan, build, test, launch. A drug program cannot use that shape, because the points at which genuinely new information arrives are not project milestones — they are regulatory and clinical events. This program's gates are placed at those events instead.
| Gate | Date | What is actually decided |
|---|---|---|
| Gate 0 — Candidate Selection | Mar 2022 | Whether to buy an option on a molecule. Small commitment, high failure probability. |
| Gate 1 — IND-Enabling Readiness | Dec 2022 | Whether the nonclinical package supports dosing humans. A safety question, not a commercial one. |
| Gate 2 — IND Submission | Jun 2023 | A submission gate. Releases no tranche — the agency's 30-day review is a regulatory clock, not a governance one. |
| Gate 3 — Phase 2 Readiness | May 2024 | Whether Phase 1 safety and PK justify dose-ranging, and across what dose span. |
| Gate 4 — Phase 3 Initiation | Jun 2026 | The largest authorization in the program — $125,800,000, 58% of base. Taken deliberately after the End-of-Phase-2 meeting, so the agency's position was known rather than assumed. |
| Gate 5 — NDA Submission | Sep 2028 | Whether the clinical, CMC and nonclinical modules will withstand review. A filing date is a manufacturing date as much as a clinical one. |
| Gate 6 — Approval & Launch | Oct 2029 | Whether launch readiness is demonstrated across supply, access and field. |
How to read this
Seventy artifacts is more than anyone reads in order. Three paths depending on why you are here.
If pharmaceutical development is new to you
- Drug Development Lifecycle Guide — the whole pathway in plain English, no background assumed.
- Program Story — how this particular program unfolded, including what it got wrong.
- Post-Launch Review — what the governance record turned out to be worth. Deliberately not a success story.
If you are assessing the program management
- Program Charter — what was authorized, and what was deliberately not.
- Development Committee Charter and Gate Decision Framework — who decides, against what, and what they may not decide at all.
- Program Budget — ceiling versus released versus spent, and why those are three different numbers.
- RAID Log and the Conditions Register — what is uncertain and what it has cost.
If you work in the field and want to check the work
- Sources & Benchmarks — every quantitative parameter with its citation, and an explicit list of what is not calibrated.
- Phase 3 Protocol Summary and the CMC Readiness Assessment — the two places domain error would show first.
- Safety Reporting Plan — regulatory timelines, verified against 21 CFR 312.32.
Where the program stands
| Dimension | Position at 15 Oct 2026 |
|---|---|
| Stage | Stage 4 — Phase 3 conduct and NDA preparation |
| Last gate | Gate 4, 30 Jun 2026 — GO WITH CONDITIONS (5-0-1) |
| Next gate | Gate 5, 30 Sep 2028 — NDA submission |
| Released to date | $201,200,000 |
| Spent to date | $101,000,000 — 50% of released authority |
| Contingency drawn | $9,050,000 of $26,040,000 |
| Enrolment | 1,684 of 2,480 randomized — 76 behind curve |
| Open gate conditions | 2 of 3, one at risk |
| Target action date | 11 Oct 2029 |
GC-03 — the payer evidence plan — is at risk, with two of five advisory boards unscheduled against a 31 March 2027 due date.
GC-01 — analytical method transfer — remains open, and it propagates: the unqualified method blocks a registration batch, which blocks a stability slot, which affects the completeness of the filing package. One technical problem, three Gate 5 criteria.
About this suite
This is a fictional program. Vitalis Therapeutics, VitaFlow, the partner organizations and every named individual are invented. The figures are internally consistent and the methodology is real, but no clinical data underlies any claim made here and nothing in this suite should be read as information about any actual product.
It exists to demonstrate stage-gate program management in a regulated development environment: how funding is released against gates, how conditions are issued and closed, how a sponsor retains accountability for outsourced conduct, and where governance authority stops.
Sources & Benchmarks records what each parameter was calibrated against, and states plainly what is not calibrated — the molecule, all clinical results, the agency interactions and the commercial case.